Literature DB >> 9427797

Epidermal growth factor-receptor expression correlates with tumor cell proliferation and prognosis in gastric cancer.

N Jonjić1, K Kovac, M Krasević, T Valković, N Ernjak, F Sasso, M Melato.   

Abstract

Currently, the most accurate prognostic indicator in gastric cancer is stage. Studies on proliferating cell nuclear antigen (PCNA) in gastric cancer have demonstrated that the PCNA labeling index correlates with depth of invasion, organ metastasis, vascular invasion, and tumor stage, suggesting that this marker may be a valuable prognostic factor. Epidermal growth factor (EGF) promotes the growth of cells of both ectodermal and mesodermal origin, and plays an important role in cellular proliferation and differentiation. Furthermore, there has been increasing evidence that growth factors and their receptors are involved in carcinogenesis. The aim of this study was to investigate the correlation between expression of the EGF-receptor (EGF-r) and proliferative activity (PCNA labeling index) in gastric cancer by immunohistochemical analysis. Our preliminary results on 56 gastric cancers indicate that the PCNA labeling index correlates with EGF-r immunoreactivity. Furthermore, survival was significantly lower in patients with EGF-r positive tumors and a high PCNA labeling index. These in situ observations suggest that EGF-r may play an important role in the growth regulation of human gastric carcinomas.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9427797

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  10 in total

Review 1.  CD74 in antigen presentation, inflammation, and cancers of the gastrointestinal tract.

Authors:  Ellen J Beswick; Victor E Reyes
Journal:  World J Gastroenterol       Date:  2009-06-21       Impact factor: 5.742

2.  Macrophage migration inhibitory factor and interleukin-8 produced by gastric epithelial cells during Helicobacter pylori exposure induce expression and activation of the epidermal growth factor receptor.

Authors:  Ellen J Beswick; Victor E Reyes
Journal:  Infect Immun       Date:  2008-05-12       Impact factor: 3.441

3.  Gefitinib and celecoxib in advanced metastatic gastrointestinal tumors: a pilot feasibility study.

Authors:  Nise H Yamaguchi; Ingrid A Mayer; Artur Malzyner; Carlos Jc de Andrade; Andre M Murad; Auro Del Giglio; Venancio Alves
Journal:  J Gastrointest Oncol       Date:  2014-02

4.  Transient receptor potential type vanilloid 1 suppresses skin carcinogenesis.

Authors:  Ann M Bode; Yong-Yeon Cho; Duo Zheng; Feng Zhu; Marna E Ericson; Wei-Ya Ma; Ke Yao; Zigang Dong
Journal:  Cancer Res       Date:  2009-01-20       Impact factor: 12.701

5.  Possible involvement of leptin and leptin receptor in developing gastric adenocarcinoma.

Authors:  Liang Zhao; Zhi-Xiang Shen; He-Sheng Luo; Lei Shen
Journal:  World J Gastroenterol       Date:  2005-12-28       Impact factor: 5.742

6.  A simple and reproducible scoring system for EGFR in colorectal cancer: application to prognosis and prediction of response to preoperative brachytherapy.

Authors:  I Zlobec; T Vuong; S Hayashi; D Haegert; L Tornillo; L Terracciano; A Lugli; J Jass
Journal:  Br J Cancer       Date:  2007-02-20       Impact factor: 7.640

7.  Induction of neuropilin-1 and vascular endothelial growth factor by epidermal growth factor in human gastric cancer cells.

Authors:  M Akagi; M Kawaguchi; W Liu; M F McCarty; A Takeda; F Fan; O Stoeltzing; A A Parikh; Y D Jung; C D Bucana; P F Mansfield; D J Hicklin; L M Ellis
Journal:  Br J Cancer       Date:  2003-03-10       Impact factor: 7.640

8.  Treatment outcome of nimotuzumab plus chemotherapy in advanced cancer patients: a single institute experience.

Authors:  Shuping Xu; Mayra Ramos-Suzarte; Xianhong Bai; Binghe Xu
Journal:  Oncotarget       Date:  2016-05-31

9.  Clinicopathologic and prognostic significance of human epidermal growth factor receptor in patients with gastric cancer: An updated meta-analysis.

Authors:  Zhiqiao Zhang; Hongfeng Tang; Jixin Lin; Yunzhao Hu; Guanying Luo; Zhaowen Luo; Canchang Cheng; Peng Wang
Journal:  Oncotarget       Date:  2017-03-07

10.  Phosphatidic Acid (PA) can Displace PPARα/LXRα Binding to The EGFR Promoter Causing its Transrepression in Luminal Cancer Cells.

Authors:  Madhu Mahankali; Terry Farkaly; Shimpi Bedi; Heather A Hostetler; Julian Gomez-Cambronero
Journal:  Sci Rep       Date:  2015-10-23       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.